Mesoblast Company Leadership
| MESO Stock | USD 13.19 0.36 2.66% |
Mesoblast employs about 73 people. The company is managed by 13 executives with a total tenure of roughly 171 years, averaging almost 13.0 years of service per executive, having 5.62 employees per reported executive. Analysis of Mesoblast's management performance can provide insight into the firm performance.
Mesoblast |
Mesoblast's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Mesoblast's future performance. Based on our forecasts, it is anticipated that Mesoblast will maintain a workforce of about 110 employees by April 2025.Mesoblast Management Team Effectiveness
The company has return on total asset (ROA) of (0.0541) % which means that it has lost $0.0541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1791) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of March 2025, Return On Tangible Assets is likely to drop to -1.14. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 18th of March 2025, Total Current Assets is likely to grow to about 116.5 M, while Total Assets are likely to drop about 583.1 M.As of the 18th of March 2025, Common Stock Shares Outstanding is likely to grow to about 1.2 B, while Net Loss is likely to drop (77.4 M).
Mesoblast Workforce Comparison
Mesoblast is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,054. Mesoblast holds roughly 73.0 in number of employees claiming about 4% of equities under Health Care industry.
Mesoblast Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Mesoblast Price Series Summation is a cross summation of Mesoblast price series and its benchmark/peer.
Mesoblast Notable Stakeholders
A Mesoblast stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mesoblast often face trade-offs trying to please all of them. Mesoblast's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mesoblast's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| LLB BCom | Joint Secretary | Profile | |
| Justin BS | Head Manufacturing | Profile | |
| Marcelo Santoro | Chief Officer | Profile | |
| Roger BA | Head Disorders | Profile | |
| Fiona See | Senior Research | Profile | |
| MS MBA | Chief Officer | Profile | |
| BSc LLB | Gen Exec | Profile | |
| FACP FACRA | CEO, Founder | Profile | |
| Eric MD | Chief Director | Profile | |
| Andrew BCom | Interim Officer | Profile | |
| Paul BPHARM | Joint Secretary | Profile | |
| MBA MS | Head Partnering | Profile | |
| Dr BSc | Scientific Officer | Profile |
About Mesoblast Management Performance
The success or failure of an entity such as Mesoblast often depends on how effective the management is. Mesoblast management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mesoblast management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mesoblast management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.08) | (1.14) | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.16) | (0.17) |
Mesoblast Workforce Analysis
Traditionally, organizations such as Mesoblast use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mesoblast within its industry.Mesoblast Manpower Efficiency
Return on Mesoblast Manpower
| Revenue Per Employee | 80.8K | |
| Revenue Per Executive | 454K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 6.8M | |
| Working Capital Per Employee | 181.1K | |
| Working Capital Per Executive | 1M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.